Photo taken from acgtfoundation.org
Aug 6, 2024, 10:23
Davoceticept as monotherapy and in combination with pembrolizumab in advanced solid tumors
Journal for ImmunoTherapy of Cancer made the following post on X:
“New JITC article: Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2).”
Authors: Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, Justin Moser, Michael Millward, Meredith McKean, Mark Voskoboynik, Rachel E. Sanborn, Jaspreet S. Grewal, Ajita Narayan, Amita Patnaik, Justin F. Gainor, Mario Sznol, Amanda Enstrom, Lori Blanchfield, Heidi LeBlanc, Heather Thomas, Michael J. Chisamore, Stanford L. Peng, Allison Naumovski.
Ajita Narayan
Allison Naumovski
Amanda Enstrom
Amita Patnaik
cancer
Diwakar Davar
Heather Thomas
Heidi LeBlanc
Jaspreet S. Grewal
Justin F. Gainor
Justin Moser
Lori Blanchfield
Ludimila Cavalcante
Mario Sznol
Mark Voskoboynik
Meredith McKean
Michael J. Chisamore
Michael Millward
Nehal Lakhani
OncoDaily
Oncology
Rachel E. Sanborn
Stanford L. Peng
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 09:55
Nov 21, 2024, 09:28
Nov 21, 2024, 09:23
Nov 21, 2024, 09:04
Nov 21, 2024, 06:49